Section Arrow
RYTM.NASDAQ
- Rhythm Pharmaceuticals
Quotes are at least 15-min delayed:2026/11/08 09:12 EST
Regular Hours
Last
 112.28
+7.26 (+6.91%)
Day High 
113.285 
Prev. Close
105.02 
1-M High
110.68 
Volume 
4.94M 
Bid
112.8
Ask
114.99
Day Low
104.31 
Open
107.1 
1-M Low
81.575 
Market Cap 
7.28B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 94.41 
20-SMA 91.51 
50-SMA 96.16 
52-W High 122.2 
52-W Low 74.5 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.91/-0.28
Enterprise Value
7.28B
Balance Sheet
Book Value Per Share
1.27
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
130.13M
Operating Revenue Per Share
0.63
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
KPTIKaryopharm Therapeutics Inc.0.0549-0.0052-8.65%-- 
INOInovio Pharmaceuticals1.215-0.235-16.21%-- 
LABTLakewood-Amedex Biotherapeutics Inc0.3863-0.1543-28.54%-- 
CDTCdt Equity Inc1.31+0.464+54.85%0PE
MRNAModerna254.19+12.73+5.27%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.